E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor

Hirokazu Ogino(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Seiji Yano(Kanazawa University Hospital), Yasuhiko Nishioka(Tokushima University), Shinji Takeuchi(Taiyo Yuden (Japan)), Hisanori Uehara(Tokushima University Hospital), Hisatsugu Goto(Tokushima University), Toshimitsu Uenaka(Kanazawa University), Akihiko Tsuruoka(Eisai (Japan)), Tadaaki Yamada(Kyoto Prefectural University of Medicine), Qi Li, Wei Wang(Nanfang Hospital), Masaki Hanibuchi(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Kenji Ikuta(Nagoya City University), Van The Trung(Kanazawa University)
Molecular Cancer Therapeutics
May 7, 2011
10.1158/1535-7163.mct-10-0707
Cited by 20

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
|Molecular Cancer|2019|316
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175